Table 1. Demographics and baseline characteristics of Korean patients randomized to treatment with exenatide twice daily or insulin lispro added to titrated insulin glargine and metformin who completed the study (per-protocol population).
| Parameter | Exenatide twice daily (n=10) | Insulin lispro (n=13) |
|---|---|---|
| Sex | ||
| Female | 6 (60.0) | 7 (53.8) |
| Male | 4 (40.0) | 6 (46.2) |
| Age, yr | 48.2±12.0 | 53.8±9.2 |
| Weight, kg | 75.8±9.9 | 74.6±16.9 |
| BMI, kg/m2 | 27.9±3.4 | 28.1±4.4 |
| HbA1c, % | 8.2±1.0 | 8.2±0.6 |
| Fasting glucose, mmol/L | 5.7±2.0 | 5.3±1.4 |
| Duration of diabetes at screening, yr | 11.1±5.4 | 13.6±5.8 |
Values are presented as number (%) or mean±standard deviation.
BMI, body mass index; HbA1c, glycosylated hemoglobin.